# Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome

> **NCT03031821** · PHASE3 · TERMINATED · sponsor: **Canadian Urologic Oncology Group** · enrollment: 168 (actual)

## Conditions studied

- Prostate Cancer
- Metabolic Syndrome

## Interventions

- **DRUG:** Metformin
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03031821
- **Lead sponsor:** Canadian Urologic Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-12
- **Primary completion:** 2023-11-24
- **Final completion:** 2023-11-24
- **Target enrollment:** 168 (ACTUAL)
- **Why stopped:** Manufacturer discontinued the production of study drugs.
- **Last updated:** 2024-10-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03031821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03031821, "Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03031821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*